<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033406</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-2482-3001</org_study_id>
    <nct_id>NCT04033406</nct_id>
  </id_info>
  <brief_title>Study of VIR-2482 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Efficacy of VIR-2482 for the Prevention of Influenza A Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vir Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2 study in which healthy volunteers will receive VIR-2482 or placebo and
      will be assessed for safety, pharmacokinetics, immunogenicity, and efficacy of VIR-2482 in
      preventing Influenza A illness.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events.</measure>
    <time_frame>Up to 8 months post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormalities in vital signs, electrocardiogram (ECG), and clinically significant laboratory findings.</measure>
    <time_frame>Up to 8 months post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory-confirmed influenza A illness.</measure>
    <time_frame>Up to 8 months post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with culture-confirmed influenza A illness</measure>
    <time_frame>Up to 8 months post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and duration of participant-reported signs and symptoms of influenza like illness (ILI) due to influenza A</measure>
    <time_frame>Up to 8 months post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the viral load present in nasopharyngeal secretions at the time of initial symptomatic presentation by RT-qPCR and viral culture</measure>
    <time_frame>Up to 8 months post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of VIR-2482 in serum</measure>
    <time_frame>Up to 8 months post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titers (if applicable) of anti-drug antibody (ADA) to VIR-2482</measure>
    <time_frame>Up to 8 months post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2860</enrollment>
  <condition>Influenza A</condition>
  <arm_group>
    <arm_group_label>VIR-2482</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIR-2482</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIR-2482</intervention_name>
    <description>VIR-2482 given by intramuscular injection</description>
    <arm_group_label>VIR-2482</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile normal saline (0.9% NaCl) given by intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male or Female age 18 to &lt; 65 years

          -  Body mass index (BMI) of 18.0 kg/m^2 to 35.0kg/m^2

        Exclusion Criteria:

          -  Any prior or planned influenza vaccination for the upcoming flu season

          -  Any clinically significant chronic or acute medical condition that makes the volunteer
             unsuitable for participation

          -  History of influenza-like illness or confirmed influenza infection within 3 months
             prior to randomization.

          -  Fever-like illness within 5 days of randomization.

          -  History or clinical evidence of conditions considered high risk for developing
             influenza-related complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

